Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Dose De-escalation of Orally Administered Filgotinib in Subjects With Ulcerative Colitis in Clinical Remission

NCT05479058 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.

NCT NCT05479058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Dose De-escalation of Orally Administered Filgotinib in Subjects With Ulcerative Colitis in Clinical Remission
Lead sponsor
Lakefront Biotherapeutics NV
Phase
Phase 3
Overall status
Terminated
Start date
July 26, 2022
Completion date
October 9, 2023
Enrollment
22 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis